No Data
No Data
No Data
No Data
No Data
Fosun Pharmaceutical (600196.SH): Holding subsidiary Fuhong Hanlin (02696) was approved for drug clinical trials
Fosun Pharmaceutical (600196.SH) announced that Shanghai Fuhong Hanlin Biotechnology Co., Ltd., a holding subsidiary of the company...
Zhitong FinanceApr 17 16:40
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
China's drug regulator granted clinical trial approval to a Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) subsidiary for its HLX53 combination with slulimumab and bevacizumab injections
MT NewswiresApr 18 17:51
Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year
Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.
cls.cnApr 18 08:10
Fosun Pharmaceutical (02196.HK) held a board meeting on April 29 to consider and approve the first quarter results
Gelonghui, April 17, 丨 Fosun Pharmaceutical (02196.HK) announced that it will hold a board meeting on April 29, 2024 (Monday) to consider, approve and publish the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024.
Gelonghui FinanceApr 17 16:50
復星醫藥:董事會會議日期
Futu NewsApr 17 16:47 · Announcements
Express News | Fosun Pharmaceutical: The holding subsidiary received the registration application for sodium phosphonate injection
BreakingsApr 17 16:35
No Data
No Data